ZLZhiguang Li

Zhiguang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhiguang Li has a total of 277 co-authors. Here are the top co-authors by number of shared publications:

  • Xuehong Zhang

    9 shared publications
  • Jinhua Zhang

    The College of Life Science and Bioengineering, Beijing Jiaotong University, Beijing, China

    8 shared publications
  • Tao Chen

    Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas 72079

    8 shared publications
  • Yu Zhang

    Center of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning, China

    8 shared publications
  • Zhihai Qin

    Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China

    8 shared publications
  • Dekang Lv

    Center of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning, China

    7 shared publications

Latest Publications

  • Open Access

    Data from YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity

    by Xuhao Ni, Jinhui Tao, Joseph Barbi, Qian Chen, Benjamin V. Park, Zhiguang Li, Nailing Zhang, Andriana Lebid, Anjali Ramaswamy, Ping Wei, et al.

    Regulatory T cells (Treg) are critical for maintaining self-tolerance and immune homeostasis, but their suppressive function can impede effective antitumor immune responses. FOXP3 is a transcription factor expressed in Tregs that is required for their function. However, the pathways and microenvironmental cues governing FOXP3 expression and Treg function are not completely understood. Herein, we report that YAP, a coactivator of the Hippo pathway, is highly expressed in Tregs and bolsters FOXP3 expression and Treg function in vitro and in vivo. This potentiation stemmed from YAP-dependent upregulation of activin signaling, which amplifies TGFβ/SMAD activation in Tregs. YAP deficiency resulted in dysfunctional Tregs unable to suppress antitumor immunity or promote tumor growth in mice. Chemical YAP antagonism and knockout or blockade of the YAP-regulated activin receptor similarly improved antitumor immunity. Thus, we identify YAP as an unexpected amplifier of a Treg-reinforcing pathway with significant potential as an anticancer immunotherapeutic target.Significance: Tregs suppress antitumor immunity, and pathways supporting their function can be novel immunotherapy targets. Here, the selective expression of YAP by Tregs, its importance for their function, and its unexpected enhancement of pro-Treg Activin/SMAD signaling are reported, as are validations of potential cancer-fighting antagonists of YAP and its regulatory targets. Cancer Discov; 8(8); 1026–43. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 899

  • Open Access

    Data from YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity

    by Xuhao Ni, Jinhui Tao, Joseph Barbi, Qian Chen, Benjamin V. Park, Zhiguang Li, Nailing Zhang, Andriana Lebid, Anjali Ramaswamy, Ping Wei, et al.

    Regulatory T cells (Treg) are critical for maintaining self-tolerance and immune homeostasis, but their suppressive function can impede effective antitumor immune responses. FOXP3 is a transcription factor expressed in Tregs that is required for their function. However, the pathways and microenvironmental cues governing FOXP3 expression and Treg function are not completely understood. Herein, we report that YAP, a coactivator of the Hippo pathway, is highly expressed in Tregs and bolsters FOXP3 expression and Treg function in vitro and in vivo. This potentiation stemmed from YAP-dependent upregulation of activin signaling, which amplifies TGFβ/SMAD activation in Tregs. YAP deficiency resulted in dysfunctional Tregs unable to suppress antitumor immunity or promote tumor growth in mice. Chemical YAP antagonism and knockout or blockade of the YAP-regulated activin receptor similarly improved antitumor immunity. Thus, we identify YAP as an unexpected amplifier of a Treg-reinforcing pathway with significant potential as an anticancer immunotherapeutic target.Significance: Tregs suppress antitumor immunity, and pathways supporting their function can be novel immunotherapy targets. Here, the selective expression of YAP by Tregs, its importance for their function, and its unexpected enhancement of pro-Treg Activin/SMAD signaling are reported, as are validations of potential cancer-fighting antagonists of YAP and its regulatory targets. Cancer Discov; 8(8); 1026–43. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 899

  • Open Access

    Figure S1 to S13 from YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity

    by Xuhao Ni, Jinhui Tao, Joseph Barbi, Qian Chen, Benjamin V. Park, Zhiguang Li, Nailing Zhang, Andriana Lebid, Anjali Ramaswamy, Ping Wei, et al.

    Supplementary Figure S1. Expression and activation of YAP and other Hippo Pathway factors in CD4+ T cell subsets; Supplementary Figure S2. Characterization of the baseline immune profile of T cell-specific YAP-deficient mice; Supplementary Figure S3. Haematoxylin and eosin staining of lung, kidney, liver, small intestine and stomach sections from 21-day-old wild-type and YAPcKO mice; Supplementary Figure S4. The effect on iTreg generation under optimal TGFβ concentration; Supplementary Figure S5. Treg-specific YAP deficiency slows the growth of implanted MC38-colon tumors and boosts anti-tumor immunity; Supplementary Figure S6. Treg-specific YAP deficiency slows the growth of implanted EL4 thymomas and boosts anti-tumor immunity; Supplementary Figure S7. The effect of YAP inhibition monotherapy and combinational immunotherapy treatments on the immune constituents of the tumor microenvironment; Supplementary Figure S8. Correlation of gene expression in stimulated wild-type and YAP cKO derived Tregs; Supplementary Figure S9. Both Activin A and its receptor (ACVR1c) are upregulated during the course of iTreg differentiation; Supplementary Figure S10. Effect of AcVR1c deficiency on iTreg differentiation; Supplementary Figure S11. Supplemental Activin fails to rescue iTreg generation when SMAD2/3 levels are lacking; Supplementary Figure S12. Effects of GM-Vac and Anti-Activin treatment on B16 tumor progression in Wild Type and AcVR1c KO mice; Supplementary Figure S13. A model for YAP-mediated TGFβ/SMAD signaling enhancement

  • Open Access

    Figure S1 to S13 from YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity

    by Xuhao Ni, Jinhui Tao, Joseph Barbi, Qian Chen, Benjamin V. Park, Zhiguang Li, Nailing Zhang, Andriana Lebid, Anjali Ramaswamy, Ping Wei, et al.

    Supplementary Figure S1. Expression and activation of YAP and other Hippo Pathway factors in CD4+ T cell subsets; Supplementary Figure S2. Characterization of the baseline immune profile of T cell-specific YAP-deficient mice; Supplementary Figure S3. Haematoxylin and eosin staining of lung, kidney, liver, small intestine and stomach sections from 21-day-old wild-type and YAPcKO mice; Supplementary Figure S4. The effect on iTreg generation under optimal TGFβ concentration; Supplementary Figure S5. Treg-specific YAP deficiency slows the growth of implanted MC38-colon tumors and boosts anti-tumor immunity; Supplementary Figure S6. Treg-specific YAP deficiency slows the growth of implanted EL4 thymomas and boosts anti-tumor immunity; Supplementary Figure S7. The effect of YAP inhibition monotherapy and combinational immunotherapy treatments on the immune constituents of the tumor microenvironment; Supplementary Figure S8. Correlation of gene expression in stimulated wild-type and YAP cKO derived Tregs; Supplementary Figure S9. Both Activin A and its receptor (ACVR1c) are upregulated during the course of iTreg differentiation; Supplementary Figure S10. Effect of AcVR1c deficiency on iTreg differentiation; Supplementary Figure S11. Supplemental Activin fails to rescue iTreg generation when SMAD2/3 levels are lacking; Supplementary Figure S12. Effects of GM-Vac and Anti-Activin treatment on B16 tumor progression in Wild Type and AcVR1c KO mice; Supplementary Figure S13. A model for YAP-mediated TGFβ/SMAD signaling enhancement

  • Open Access

    Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

    by Zhiguang Li, Jing Jiang, Zibing Wang, Jinhua Zhang, Mingjie Xiao, Chunhui Wang, Yu Lu, Zhihai Qin

    Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

  • Open Access

    Supplementary Figure 3 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

    by Zhiguang Li, Jing Jiang, Zibing Wang, Jinhua Zhang, Mingjie Xiao, Chunhui Wang, Yu Lu, Zhihai Qin

    Supplementary Figure 3 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

  • Open Access

    Supplementary Figure 1 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

    by Zhiguang Li, Jing Jiang, Zibing Wang, Jinhua Zhang, Mingjie Xiao, Chunhui Wang, Yu Lu, Zhihai Qin

    Supplementary Figure 1 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

  • Open Access

    Data from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

    by Zhiguang Li, Jing Jiang, Zibing Wang, Jinhua Zhang, Mingjie Xiao, Chunhui Wang, Yu Lu, Zhihai Qin

  • Open Access

    Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

    by Zhiguang Li, Jing Jiang, Zibing Wang, Jinhua Zhang, Mingjie Xiao, Chunhui Wang, Yu Lu, Zhihai Qin

    Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

  • Open Access

    WAFNRLTG: A Novel Model for Predicting LncRNA Target Genes Based on Weighted Average Fusion Network Representation Learning Method

    by Jianwei Li, Zhenwu Yang, Duanyang Wang, Zhiguang Li

    Long non-coding RNAs (lncRNAs) do not encode proteins, yet they have been well established to be involved in complex regulatory functions, and lncRNA regulatory dysfunction can lead to a variety of human complex diseases. LncRNAs mostly exert their functions by regulating the expressions of target genes, and accurate prediction of potential lncRNA target genes would be helpful to further understanding the functional annotations of lncRNAs. Considering the limitations in traditional computational methods for predicting lncRNA target genes, a novel model which was named Weighted Average Fusion Network Representation learning for predicting LncRNA Target Genes (WAFNRLTG) was proposed. First, a novel heterogeneous network was constructed by integrating lncRNA sequence similarity network, mRNA sequence similarity network, lncRNA-mRNA interaction network, lncRNA-miRNA interaction network and mRNA-miRNA interaction network. Next, four popular network representation learning methods were utilized to gain the representation vectors of lncRNA and mRNA nodes. Then, the representations of lncRNAs and target genes in the heterogeneous network were obtained with the weighted average fusion network representation learning method. Finally, we merged the representations of lncRNAs and related target genes to form lncRNA-gene pairs, trained the XGBoost classifier and predicted potential lncRNA target genes. In five-cross validations on the training and independent datasets, the experimental results demonstrated that WAFNRLTG obtained better AUC scores (0.9410, 0.9350) and AUPR scores (0.9391, 0.9350). Moreover, case studies of three common lncRNAs were performed for predicting their potential lncRNA target genes and the results confirmed the effectiveness of WAFNRLTG. The source codes and all data of WAFNRLTG can be freely downloaded at https://github.com/HGDYZW/WAFNRLTG.